Suchita Rastogi, Ph.D.
doi : 10.1056/NEJMp2035279
N Engl J Med 2021; 384:885-887
Omar S. Haque, M.D., Ph.D., Michael A. Stein, J.D., Ph.D., and Amelia Marvit
doi : 10.1056/NEJMp2031013
N Engl J Med 2021; 384:888-891
Katharine Van Tassel, J.D., M.P.H., Carmel Shachar, J.D., M.P.H., and Sharona Hoffman, J.D., L.L.M., S.J.D.
doi : 10.1056/NEJMp2034438
N Engl J Med 2021; 384:e34
Mary Kathryn Poole, M.P.H., Sheila E. Fleischhacker, Ph.D., J.D., and Sara N. Bleich, Ph.D.
doi : 10.1056/NEJMp2033629
N Engl J Med 2021; 384:e35
Teresa A. Hillier, M.D., Kathryn L. Pedula, M.S., Keith K. Ogasawara, M.D., Kimberly K. Vesco, M.D., M.P.H., Caryn E.S. Oshiro, Ph.D., Suzanne L. Lubarsky, M.D., and Jan Van Marter, M.P.A., R.N.
doi : 10.1056/NEJMoa2026028
N Engl J Med 2021; 384:895-904
Gestational diabetes mellitus is common and is associated with an increased risk of adverse maternal and perinatal outcomes. Although experts recommend universal screening for gestational diabetes, consensus is lacking about which of two recommended screening approaches should be used.
ACTIV-3/TICO LY-CoV555 Study Group*
doi : 10.1056/NEJMoa2033130
N Engl J Med 2021; 384:905-914
LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on the effect of this antibody in patients who are hospitalized with Covid-19.
Giovanni Baranello, M.D., Ph.D., Basil T. Darras, M.D., John W. Day, M.D., Ph.D., Nicolas Deconinck, M.D., Ph.D., Andrea Klein, M.D., Riccardo Masson, M.D., Eugenio Mercuri, M.D., Ph.D., Kristy Rose, Ph.D., Muna El-Khairi, Ph.D., Marianne Gerber, Ph.D., Ksenija Gorni, M.D., Ph.D., Omar Khwaja, M.D., Ph.D., Heidemarie Kletzl, Ph.D., Renata S. Scalco, M.D., Ph.D., Timothy Seabrook, Ph.D., Paulo Fontoura, M.D., Ph.D., and Laurent Servais, M.D., Ph.D. for the FIREFISH Working Group*
doi : 10.1056/NEJMoa2009965
N Engl J Med 2021; 384:915-923
Type 1 spinal muscular atrophy is a rare, progressive neuromuscular disease that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam is an orally administered, small molecule that modifies SMN2 pre–messenger RNA splicing and increases levels of functional SMN protein.
Eric J. Duncavage, M.D., Molly C. Schroeder, Ph.D., Michele O’Laughlin, B.S., Roxanne Wilson, B.S., Sandra MacMillan, B.S., Andrew Bohannon, B.S., Scott Kruchowski, B.S., John Garza, B.S., Feiyu Du, M.S., Andrew E.O. Hughes, M.D., Ph.D., Josh Robinson, B.A., Emma Hughes, B.S., Sharon E. Heath, Jack D. Baty, B.A., Julie Neidich, M.D., Matthew J. Christopher, M.D., Ph.D., Meagan A. Jacoby, M.D., Ph.D., Geoffrey L. Uy, M.D., Robert S. Fulton, M.S., Christopher A. Miller, Ph.D., Jacqueline E. Payton, M.D., Ph.D., Daniel C. Link, M.D., Matthew J. Walter, M.D., Peter Westervelt, M.D., Ph.D., John F. DiPersio, M.D., Ph.D., Timothy J. Ley, M.D., and David H. Spencer, M.D., Ph.D.
doi : 10.1056/NEJMoa2024534
N Engl J Med 2021; 384:924-935
Genomic analysis is essential for risk stratification in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Whole-genome sequencing is a potential replacement for conventional cytogenetic and sequencing approaches, but its accuracy, feasibility, and clinical utility have not been demonstrated.
Hirokazu Usui, M.D., Ph.D., and Makio Shozu, M.D., Ph.D.
doi : 10.1056/NEJMoa2005756
N Engl J Med 2021; 384:936-943
A complete hydatidiform mole (CHM) is a conceptus with only sperm-derived chromosomes. Here, we report on a CHM with genomic DNA identical to that of the paternal somatic cells. The CHM developed in a woman who had undergone intrauterine implantation of a blastocyst obtained through in vitro injection of a presumed round spermatid into one of her oocytes. The CHM was genetically identical to peripheral white cells of her husband and contained no maternally derived nuclear DNA. We hypothesize that a spermatogonium, rather than a round spermatid, was inadvertently selected for the procedure. The CHM developed into a gestational trophoblastic neoplasia, which resolved after chemotherapy. (Funded by the Japan Society for the Promotion of Science.)
Rachael L. Niederer, M.B., Ch.B., Ph.D., and Haya H. Al-Ani, M.B., Ch.B.
doi : 10.1056/NEJMicm2005549
N Engl J Med 2021; 384:952
Gunar Günther, M.D., and Chalese Einbeck, M.D.
doi : 10.1056/NEJMicm2028047
N Engl J Med 2021; 384:e36
Pavan K. Bendapudi, M.D., Michael J. Whalen, M.D., Manuella Lahoud-Rahme, M.D., and Julian A. Villalba, M.D.
doi : 10.1056/NEJMcpc2027093
N Engl J Med 2021; 384:953-963
Brian Casey, M.D.
doi : 10.1056/NEJMe2100902
N Engl J Med 2021; 384:965-966
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., Jonathan Abraham, M.D., Ph.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2104138
N Engl J Med 2021; 384:e48
Peter C. Butler, M.D.
doi : 10.1056/NEJMcibr2028410
N Engl J Med 2021; 384:967-969
doi : 10.1056/NEJMc2033779
N Engl J Med 2021; 384:970-971
doi : 10.1056/NEJMc2036233
N Engl J Med 2021; 384:971-973
doi : 10.1056/NEJMc2035891
N Engl J Med 2021; 384:973-976
doi : 10.1056/NEJMc2034424
N Engl J Med 2021; 384:976-977
doi : 10.1056/NEJMc2101226
N Engl J Med 2021; 384:977-978
Peter A. Ubel, M.D.
doi : 10.1056/NEJMpv2101203
N Engl J Med 2021; 384:e39
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟